Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease-Reference-Cited by-同舟云学术

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Published:2021-02-01 Issue:2 Volume:78 Page:149
ISSN:2168-6149
Container-title:JAMA Neurology
language:en
Short-container-title:JAMA Neurol

Author:

Janelidze Shorena¹,Berron David¹,Smith Ruben¹²,Strandberg Olof¹,Proctor Nicholas K.³,Dage Jeffrey L.³,Stomrud Erik¹⁴,Palmqvist Sebastian¹⁴,Mattsson-Carlgren Niklas¹²⁵,Hansson Oskar¹⁴

Affiliation:

1. Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Sölvegatan, Sweden

2. Department of Neurology, Skåne University Hospital, Lund, Sweden

3. Eli Lilly and Company, Indianapolis, Indiana

4. Memory Clinic, Skåne University Hospital, Malmö, Sweden

5. Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden

Publisher

American Medical Association (AMA)

Subject

Neurology (clinical)

Link

https://jamanetwork.com/journals/jamaneurology/articlepdf/2772866/jamaneurology_janelidze_2020_oi_200082_1612851429.67851.pdf

Reference29 articles.

1. Alzheimer’s disease.;Scheltens;Lancet,2016

2. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.;Beach;J Neuropathol Exp Neurol,2012

3. NIA-AA research framework: toward a biological definition of Alzheimer’s disease.;Jack;Alzheimers Dement,2018

4. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography.;Mielke;Alzheimers Dement,2018

5. Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and Down syndrome.;Tatebe;Mol Neurodegener,2017

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer’s disease mouse model;Brain, Behavior, and Immunity;2024-11

2. Cognivue Clarity ® Characterizes Mild Cognitive Impairment and Alzheimer’s Disease in Biomarker Confirmed Cohorts in the Bio-Hermes Study;2024-09-10

3. Alzheimer’s disease biomarkers and their current use in clinical research and practice;Molecular Psychiatry;2024-09-04

4. Clinical significance of plasma candidate biomarkers of Alzheimer’s Disease;Neurologia i Neurochirurgia Polska;2024-08-28

5. Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic;Alzheimer's Research & Therapy;2024-08-21